Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

B cell lymphoma

Mucosa associated lymphoid tissue lymphoma translocation
gene 1 (MALT1)

In vitro and mouse studies identified small molecule MALT1 inhibitors that could help treat patients with the activated B cell (ABC) subtype of diffuse large
B cell lymphoma (DLBCL). In cultured ABC-DLBCL cells, phenothiazine derivatives, including the generic antipsychotic drug thioridazine, inhibited MALT1 and cell growth at 5-10 mM concentrations. In cultured ABC-DLBCL cells, a second study showed that an unrelated compound, MI-2, inhibited MALT1 and cell growth at nanomolar concentrations. In mouse models of ABC-DLBCL, both compounds decreased tumor growth compared with vehicle. Next steps for both groups include additional preclinical characterization of MALT1 inhibitors, including comparative and combination studies with other therapeutics such as Bruton's tyrosine kinase (BTK) inhibitors.

SciBX 6(2); doi:10.1038/scibx.2013.30
Published online Jan. 17, 2013

Patent and licensing status for findings in first study undisclosed

Patent application filed for MALT1 inhibitors identified in second study; available for licensing from the Cornell Center for Technology Enterprise and Commercialization

Nagel, D. et al. Cancer Cell; published online Dec. 11, 2012;
doi:10.1016/j.ccr.2012.11.002
Contact: Daniel Krappmann, German Research Center for Environmental Health, Neuherberg, Germany
e-mail:

daniel.krappmann@helmholtz-muenchen.de

Fontan, L. et al. Cancer Cell; published online Dec. 11, 2012;
doi:10.1016/j.ccr.2012.11.003
Contact: Ari Melnick, Weill Cornell Medical College, New York, N.Y.
e-mail:

amm2014@med.cornell.edu
Contact: Hao Wu, Boston Children's Hospital, Boston, Mass.
e-mail:

hao.wu@childrens.harvard.edu